Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma

Completed

• Conditions: Recurrent Childhood Rhabdomyosarcoma; Alveolar Childhood Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma

• Registration Number: NCT06040229
• Lead Sponsor: Shandong First Medical University

Brief Summary

This retrospective study is looking into mechanisms of drug therapy resistance in FFPE samples in recurrent and refractory Rhabdomyosarcoma (RMS) in pediatric patients who have experienced lung recurrence. The study employs advanced techniques such as single-cell transcriptomics and spatial transcriptomics to gain a comprehensive understanding of these mechanisms.

Detailed Description

This research seeks to enhance our understanding of drug resistance mechanisms in recurrent and refractory RMS in pediatric patients, particularly in the context of lung recurrence. The utilization of cutting-edge techniques like single-cell transcriptomics and spatial transcriptomics allows for a more in-depth and comprehensive analysis of the molecular and spatial aspects of drug resistance in this challenging pediatric cancer.

Study Timeline

• Study Start: 2023-04-01
• Primary Completion: 2023-07-01
• Status Verified: 2023-09
• Study Completion: 2023-09-01
• Study First Submitted: 2023-09-10
• Study First Submitted QC: 2023-09-10
• Last Update Submitted: 2023-09-10
• Study First Posted: 2023-09-15
• Last Update Posted: 2023-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

1. Pediatric Patients: Participants in this study should be pediatric patients, typically defined as individuals aged from infancy to 18 years old, who have been diagnosed with recurrent and refractory Rhabdomyosarcoma (RMS).
2. Lung Recurrence: Included patients must have a documented history of lung recurrence of RMS as a specific clinical manifestation.
3. Availability of FFPE Samples: Patients for whom formalin-fixed paraffin-embedded (FFPE) tissue samples are available for analysis are eligible for inclusion.

Exclusion Criteria

1. Other Histological Types: Patients with RMS of histological subtypes other than those relevant to the study focus are excluded.
2. Incomplete Clinical Data: Patients with incomplete or insufficient clinical data necessary for the study's objectives may be excluded to ensure robust analysis and interpretation of results.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gene expression pattern	2023.12.31	Identification and characterization of specific genetic alterations and gene expression patterns associated with drug therapy resistance in recurrent and refractory Rhabdomyosarcoma (RMS) in pediatric patients, particularly in cases of lung recurrence, using single-cell transcriptomics and spatial transcriptomics.

Trial Locations

Locations (1)

Jinan central hospital affiliated to Shandong First Medical University; 🇨🇳 Jinan, Shandong, China